<i>XPO1</i> mutations identify early‐stage <scp>CLL</scp> characterized by shorter time to first treatment and enhanced <scp>BCR</scp> signallingRiccardo Moia, Gianluca Gaïdano, Roberta Laureana et al.|British Journal of Haematology|2023Cited by 7
The VLA-4 integrin is constitutively active in circulating chronic lymphocytic leukemia cells via BCR autonomous signaling: a novel anchor-independent mechanism exploiting soluble blood-borne ligandsErika Tissino, Valter Gattei, Annalisa Gaglio et al.|Leukemia|2024Cited by 6
The time to first treatment is an independent predictor of overall survival in chronic lymphocytic leukemiaFortunato Morabito, Massimo Gentile, Giovanni Tripepi et al.|American Journal of Hematology|2023Cited by 1
CD49d expression is included in a revised 4‐factor model predicting outcome in patients with chronic lymphocytic leukemia treated with ibrutinib: A multicenter real‐world experienceRiccardo Bomben, Valter Gattei, Antonella Zucchetto et al.|HemaSphere|2024Cited by 1
A landscape of genetic heterogeneity in germline predisposition to familial chronic lymphocytic leukemiaLuca Laurenti, Dimitar G. Efremov, Eugenio Sangiorgi et al.|Research Square|2025Cited by 0